435 related articles for article (PubMed ID: 16919851)
1. Understanding the antitumor activity of novel tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors using CoMFA and CoMSIA.
Puntambekar DS; Giridhar R; Yadav MR
Eur J Med Chem; 2006 Nov; 41(11):1279-92. PubMed ID: 16919851
[TBL] [Abstract][Full Text] [Related]
2. Insights into the structural requirements of farnesyltransferase inhibitors as potential anti-tumor agents based on 3D-QSAR CoMFA and CoMSIA models.
Puntambekar DS; Giridhar R; Yadav MR
Eur J Med Chem; 2008 Jan; 43(1):142-54. PubMed ID: 17448576
[TBL] [Abstract][Full Text] [Related]
3. 3D-QSAR studies on malonyl coenzyme A decarboxylase inhibitors.
Patel MR; Talele TT
Bioorg Med Chem; 2007 Jul; 15(13):4470-81. PubMed ID: 17482825
[TBL] [Abstract][Full Text] [Related]
4. 3D-QSAR analysis of cycloguanil derivatives as inhibitors of A16V + S108T mutant Plasmodium falciparum dihydrofolate reductase enzyme.
Adane L; Bharatam PV
J Mol Graph Model; 2009 Nov; 28(4):357-67. PubMed ID: 19796975
[TBL] [Abstract][Full Text] [Related]
5. 3D-QSAR studies of farnesyltransferase inhibitors: a comparative molecular field analysis approach.
Puntambekar D; Giridhar R; Yadav MR
Bioorg Med Chem Lett; 2006 Apr; 16(7):1821-7. PubMed ID: 16455255
[TBL] [Abstract][Full Text] [Related]
6. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
[TBL] [Abstract][Full Text] [Related]
7. 3D-QSAR studies on the inhibitors of AP-1 and NF-kappaB mediated transcriptional activation.
Qin J; Liu H; Li J; Ren Y; Yao X; Liu M
Eur J Med Chem; 2009 Jul; 44(7):2888-95. PubMed ID: 19128859
[TBL] [Abstract][Full Text] [Related]
8. 3D-QSAR studies on triazolopiperazine amide inhibitors of dipeptidyl peptidase-IV as anti-diabetic agents.
Saqib U; Siddiqi MI
SAR QSAR Environ Res; 2009 Jul; 20(5-6):519-35. PubMed ID: 19916112
[TBL] [Abstract][Full Text] [Related]
9. 3D-QSAR with the aid of pharmacophore search and docking-based alignments for farnesyltransferase inhibitors.
Vaidya M; Weigt M; Wiese M
Eur J Med Chem; 2009 Oct; 44(10):4070-82. PubMed ID: 19515462
[TBL] [Abstract][Full Text] [Related]
10. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
11. Insight into the structural requirements of proton pump inhibitors based on CoMFA and CoMSIA studies.
Nayana MR; Sekhar YN; Nandyala H; Muttineni R; Bairy SK; Singh K; Mahmood SK
J Mol Graph Model; 2008 Oct; 27(3):233-43. PubMed ID: 18676164
[TBL] [Abstract][Full Text] [Related]
12. 3D QSAR studies on T-type calcium channel blockers using CoMFA and CoMSIA.
Doddareddy MR; Jung HK; Cha JH; Cho YS; Koh HY; Chang MH; Pae AN
Bioorg Med Chem; 2004 Apr; 12(7):1613-21. PubMed ID: 15028254
[TBL] [Abstract][Full Text] [Related]
13. 3D-QSAR CoMFA/CoMSIA studies on 5-aryl-2,2-dialkyl-4-phenyl-3(2H)-furanone derivatives, as selective COX-2 inhibitors.
Puntambekar DS; Giridhar R; Yadav MR
Acta Pharm; 2006 Jun; 56(2):157-74. PubMed ID: 16613723
[TBL] [Abstract][Full Text] [Related]
14. CoMFA and CoMSIA 3D QSAR analysis on N1-arylsulfonylindole compounds as 5-HT6 antagonists.
Doddareddy MR; Cho YS; Koh HY; Pae AN
Bioorg Med Chem; 2004 Aug; 12(15):3977-85. PubMed ID: 15246074
[TBL] [Abstract][Full Text] [Related]
15. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
Pandey G; Saxena AK
J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
[TBL] [Abstract][Full Text] [Related]
16. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
17. 3D-QSAR CoMFA/CoMSIA studies on Urokinase plasminogen activator (uPA) inhibitors: a strategic design in novel anticancer agents.
Bhongade BA; Gadad AK
Bioorg Med Chem; 2004 May; 12(10):2797-805. PubMed ID: 15110861
[TBL] [Abstract][Full Text] [Related]
18. 3D-QSAR studies on tripeptide aldehyde inhibitors of proteasome using CoMFA and CoMSIA methods.
Zhu YQ; Pei JF; Liu ZM; Lai LH; Cui JR; Li RT
Bioorg Med Chem; 2006 Mar; 14(5):1483-96. PubMed ID: 16256351
[TBL] [Abstract][Full Text] [Related]
19. Structure-based 3D-QSAR studies on heteroarylpiperazine derivatives as 5-HT3 receptor antagonists.
Zhou YJ; Zhu LP; Tang Y; Ye DY
Eur J Med Chem; 2007 Jul; 42(7):977-84. PubMed ID: 17331624
[TBL] [Abstract][Full Text] [Related]
20. Understanding the antitumor activity of novel hydroxysemicarbazide derivatives as ribonucleotide reductase inhibitors using CoMFA and CoMSIA.
Raichurkar AV; Kulkarni VM
J Med Chem; 2003 Oct; 46(21):4419-27. PubMed ID: 14521406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]